Researchers have discovered that certain components of so-called 'good' cholesterol -- high-density lipoproteins (HDL) -- may be associated with an increased prevalence of cardiovascular disease.
The global cardiometabolic drugs market is projected to grow from US$ 50 billion in 2021 to over US$ 70 billion by 2032, with a CAGR of 4% to 5%. Sales are expected to surpass US$ 55 billion by 2022, ...